SELLAS Life Sciences CEO Angelos Stergiou and "Some Future Day" author Marc Beckman predict artificial intelligence will ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...

A Bay Area biotech is suing its insurance company to cover costs associated with patients allegedly injured during clinical ...

An update from Evaxion Biotech ( ($EVAX) ) is now available. On January 15, 2025, Evaxion Biotech announced the completion of ...

The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.

A temporary freeze on meetings on the National Institutes of Health could lead to delays in disbursing research grants and in ...

Anixa Biosciences CEO Amit Kumar discusses the biotech’s plans for advancing a breast cancer vaccine in 2025. The cancer ...

The company on Wednesday announced it paid $47 million up front to license MRG007, a drug developed by Lepu Biopharma, a Shanghai-based developer of cancer therapies. MRG007 is an antibody drug ...

SELLAS Life Sciences CEO Angelos Stergiou says his company is already on the cusp of a finalized leukemia vaccine, but another game-changer – personalized cancer vaccines – could be on the ...